知镜 Cognispect · 医学文献与研究工作台

Intraocular Pressure-Lowering Effect of Netarsudil Across Glaucoma Severity.

Yoon H, Lee J, Hong H, Moon S.
Journal of glaucoma · 2026-08-28 · PMID 42743074

文献摘要

Precis Netarsudil lowered IOP across all glaucoma severity stages; however, its durability appeared reduced in patients with systemic hypertension, suggesting the need for closer follow-up. Purpose To evaluate the intraocular pressure (IOP)-lowering effect of netarsudil 0.02% across different stages of glaucoma severity and to investigate the influence of systemic hypertension on treatment response over time. Methods This retrospective study included 113 eyes of 113 patients with glaucoma who initiated netarsudil 0.02% between December 2024 and December 2025. Patients were classified into early (mean deviation [MD] >-6 dB), moderate (-6 to -12 dB), and advanced ( Results Baseline IOP was comparable across severity groups. Netarsudil produced a significant reduction in IOP over time (P Conclusions Netarsudil was associated with a significant IOP-lowering effect across all stages of glaucoma, without significant differences according to disease severity. However, the durability of its effect may be influenced by systemic hypertension, suggesting the need for closer monitoring in hypertensive patients.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。